202 related articles for article (PubMed ID: 35112435)
1. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
Shi Y; Zheng H; Wang M; Ding S
Helicobacter; 2022 Apr; 27(2):e12878. PubMed ID: 35112435
[TBL] [Abstract][Full Text] [Related]
2. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
3. Effect of Helicobacter pylori on immunotherapy is gaining more attention.
Shi Y; Zheng H; Guo Z; Deng R; Yu W; Song Y; Ding S
Helicobacter; 2022 Oct; 27(5):e12925. PubMed ID: 36036113
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT1 Signaling Pathway Is an Early Response to
Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
[No Abstract] [Full Text] [Related]
5. Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation.
Mommersteeg MC; Yu BT; van den Bosch TPP; von der Thüsen JH; Kuipers EJ; Doukas M; Spaander MCW; Peppelenbosch MP; Fuhler GM
Helicobacter; 2022 Oct; 27(5):e12917. PubMed ID: 35899973
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori infection and PD-L1 expression in gastric cancer: A meta-analysis.
Zhu Y; Zhu F; Ba H; Chen J; Bian X
Eur J Clin Invest; 2023 Feb; 53(2):e13880. PubMed ID: 36164962
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
8. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
Mudassar F; Shen H; Cook KM; Hau E
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
[TBL] [Abstract][Full Text] [Related]
9. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
11. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
Jiang Y; Zhao X; Fu J; Wang H
Front Immunol; 2020; 11():339. PubMed ID: 32226426
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
13. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
Cao Y; Li W; Wang Z; Pang H
Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
[TBL] [Abstract][Full Text] [Related]
14. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
15. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Che H; Xiong Q; Ma J; Chen S; Wu H; Xu H; Hou B
BMC Cancer; 2022 Aug; 22(1):904. PubMed ID: 35986342
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter urease suppresses cytotoxic CD8+ T-cell responses through activating Myh9-dependent induction of PD-L1.
Wu J; Zhu X; Guo X; Yang Z; Cai Q; Gu D; Luo W; Yuan C; Xiang Y
Int Immunol; 2021 Aug; 33(9):491-504. PubMed ID: 34297096
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
[TBL] [Abstract][Full Text] [Related]
20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
